{"id":13457,"date":"2025-12-18T09:00:00","date_gmt":"2025-12-18T08:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=news_item&#038;p=13457"},"modified":"2026-03-10T11:56:00","modified_gmt":"2026-03-10T10:56:00","slug":"neue-rueckverguetung-fur-brust-und-lungenkrebs","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/","title":{"rendered":"Bundesamt f\u00fcr Gesundheit nimmt zwei neue Brust- und Lungenkrebs Indikationen f\u00fcr Pembrolizumab in Spezialit\u00e4tenliste zur R\u00fcckverg\u00fctung auf"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-13457","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch<\/title>\n<meta name=\"description\" content=\"Das Bundesamt f\u00fcr Gesundheit nimmt Pembrolizumab (KEYTRUDA\u00ae) f\u00fcr TNBC und NSCLC neu in die Spezialit\u00e4tenliste zur R\u00fcckverg\u00fctung auf.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch\" \/>\n<meta property=\"og:description\" content=\"Das Bundesamt f\u00fcr Gesundheit nimmt Pembrolizumab (KEYTRUDA\u00ae) f\u00fcr TNBC und NSCLC neu in die Spezialit\u00e4tenliste zur R\u00fcckverg\u00fctung auf.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T10:56:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/\",\"url\":\"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/\",\"name\":\"Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/de\/#website\"},\"datePublished\":\"2025-12-18T08:00:00+00:00\",\"dateModified\":\"2026-03-10T10:56:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/de\/#website\",\"url\":\"https:\/\/www.msd.ch\/de\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch","description":"Das Bundesamt f\u00fcr Gesundheit nimmt Pembrolizumab (KEYTRUDA\u00ae) f\u00fcr TNBC und NSCLC neu in die Spezialit\u00e4tenliste zur R\u00fcckverg\u00fctung auf.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/","og_locale":"en_US","og_type":"article","og_title":"Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch","og_description":"Das Bundesamt f\u00fcr Gesundheit nimmt Pembrolizumab (KEYTRUDA\u00ae) f\u00fcr TNBC und NSCLC neu in die Spezialit\u00e4tenliste zur R\u00fcckverg\u00fctung auf.","og_url":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/","og_site_name":"msd.ch","article_modified_time":"2026-03-10T10:56:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/","url":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/","name":"Pembrolizumab: Neue BAG-R\u00fcckverg\u00fctung f\u00fcr TNBC und NSCLC - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2025-12-18T08:00:00+00:00","dateModified":"2026-03-10T10:56:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/news\/neue-rueckverguetung-fur-brust-und-lungenkrebs\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/13457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":19,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/13457\/revisions"}],"predecessor-version":[{"id":13775,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/13457\/revisions\/13775"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=13457"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=13457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}